Journal
NEUROMOLECULAR MEDICINE
Volume 21, Issue 4, Pages 344-368Publisher
HUMANA PRESS INC
DOI: 10.1007/s12017-019-08530-0
Keywords
Stroke; Biomarker; Genomics; Proteomics; Diagnosis; Management
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Heart and Stroke Foundation
- University Hospital Foundation
- National Institutes of Health (NIH)
Ask authors/readers for more resources
Biomarkers are objective indicators used to assess normal or pathological processes, evaluate responses to treatment and predict outcomes. Many blood biomarkers already guide decision-making in clinical practice. In stroke, the number of candidate biomarkers is constantly increasing. These biomarkers include proteins, ribonucleic acids, lipids or metabolites. Although biomarkers have the potential to improve the diagnosis and the management of patients with stroke, there is currently no marker that has demonstrated sufficient sensitivity, specificity, rapidity, precision, and cost-effectiveness to be used in the routine management of stroke, thus highlighting the need for additional work. A better standardization of clinical, laboratory and statistical procedures between centers is indispensable to optimize biomarker performance. This review focuses on blood biomarkers that have shown promise for translation into clinical practice and describes some newly reported markers that could add to routine stroke care. Avenues for the discovery of new stroke biomarkers and future research are discussed. The description of the biomarkers is organized according to their expected application in clinical practice: diagnosis, treatment decision, and outcome prediction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available